LivaNova (NASDAQ:LIVN) Earns “Buy” Rating from Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They currently have a $64.00 target price on the stock. Needham & Company LLC’s target price suggests a potential upside of 63.10% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Barclays dropped their price objective on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research note on Friday, March 7th. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Mizuho dropped their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $61.17.

LivaNova Trading Up 1.8 %

NASDAQ LIVN opened at $39.24 on Monday. LivaNova has a 12 month low of $36.85 and a 12 month high of $64.47. The company has a 50-day moving average of $46.00 and a 200-day moving average of $49.07. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.13 billion, a P/E ratio of 93.43 and a beta of 1.10.

Institutional Trading of LivaNova

Several large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its position in LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after acquiring an additional 219 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after buying an additional 289 shares during the last quarter. Atria Investments Inc boosted its stake in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after buying an additional 331 shares during the last quarter. Xponance Inc. boosted its stake in shares of LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after buying an additional 445 shares during the last quarter. Finally, Mariner LLC boosted its stake in shares of LivaNova by 8.4% during the 4th quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after buying an additional 446 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.